To this purpose, clinical trials investigating anti-EGFR drugs including nimotuzumab, gefitinib, and erlotinib have been conducted, showing some benefits but only in small subsets of DIPG patients [16,17,18]. Here, EGFR is linked to diffuse intrinsic pontine glioma.